Table 2 Extended differences between patients that received doses above and below 5 mg/kg.

From: Trends and practices following the 2016 hydroxychloroquine screening guidelines

 

 ≤ 5 mg/kg (n = 74)

 > 5 mg/kg (n = 92)

p value

Weight in kg (mean [CI])

81.5 (76.5, 86.5)

63.9 (61.8, 66.0)

 < 0.001a

Duration of therapy in years (mean [CI])

5.0 (3.9, 6.2)

5.5 (4.2, 6.7)

0.594

Cumulative lifetime dose in grams (mean [CI])

561.2 (429.2, 693.1)

783.6 (603.5, 963.6)

0.060

Indication for HCQ therapy (total [%])

   

 1. UCTD, MCTD

3 (4.1%)

5 (5.4%)

0.711

 2. RA

13 (17.6%)

18 (19.6%)

 

 3. SLE, Discoid lupus

41 (55.4%)

46 (50.0%)

 

 4. Inflammatory arthritis, uncertain

3 (4.1%)

8 (8.7%)

 

 5. Sjögren

9 (12.2%)

7 (7.6%)

 

 6. Otherb

1 (1.4%)

4 (4.3%)

 

 7. Multiplec

4 (5.4%)

4 (4.3%)

 

Attending Group (% group)

   

 Ophthalmologist

18 (24.3%)

19 (20.7%)

0.695

 Optometry

15 (20.3%)

24 (26.1%)

 

 Retina

41 (55.4%)

49 (53.3%)

 

High-Riskd (% group)

   

 No

43 (58.9%)

67 (72.8%)

0.069

 Yes

30 (41.1%)

25 (27.2%)

 
  1. HCQ Hydroxychloroquine, UCTD Undifferentiated connective tissue disease, MCTD Mixed connective tissue disease, RA Rheumatoid arthritis, SLE Systemic lupus erythematosus.
  2. aBold p-values are less than 0.05.
  3. bOther diseases involved: Lichen planus, Dermatomyositis, Palindromic rheumatism, Unspecified dermatitis, Lichen sclerosis, Systemic sclerosis, Osteoarthritis, Autoimmune neutropenia, Psoriatic arthritis.
  4. cMultiple autoimmune diseases involved: SLE + Dermatomyositis, Sjögren + Scleroderma, SLE + Sjögren, SLE + RA, RA + Sjögren, SLE + Scleroderma, RA + Sjögren + Lichen sclerosis, SLE + Juvenile idiopathic arthritis, SLE + Psoriatic arthritis.
  5. dHigh-risk features including renal disease, concomitant tamoxifen use, known retinal or macular disease.
Back to article page